NewLink Genetics to Host Its Second Quarter 2015 Earnings Conference Call on July 31, 2015

AMES, Iowa, July 24, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company at the forefront of developing novel immuno-oncology and infectious-disease products to improve the lives of  patients, reported that it will release its second quarter 2015 financial results on Friday, July 31, 2015.  The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on clinical and business development activities.

NewLink’s senior management team will host the conference call, which will be open to all listeners.  There will also be a question and answer session following the prepared remarks.

Access to the live call is available by dialing (855) 469-0612 (U.S.) or (484) 756-4268 (international) five minutes prior to the start of the call.    A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and using the passcode 94565879.  The replay will be available for two weeks from the date of the call. 

About NewLink Genetics Corporation

NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology products to improve the lives of patients with cancer. Our portfolio of product candidates is poised to further cancer-treatment research.  NewLink Genetics is actively researching a unique, multifaceted immuno-oncology treatment strategy based on its HyperAcute® Immunotherapies, which are designed to educate patients’ natural defenses to target cancer directly, and IDO Pathway Inhibitors, which act either alone or in combination with other treatment options to prevent tumor cells from evading the immune response.  NewLink’s Ebola vaccine candidate is being tested in advanced clinical trials in Africa.  For more information, please visit http://www.newlinkgenetics.com.

Corporate Contact:
Jack Henneman, Chief Financial Officer
515-598-2561
[email protected]

Investors:
Donna LaVoie or Kristina Coppola
LaVoieHealthScience
617-374-8800 X105/7

Media:
David Connolly
LaVoieHealthScience
617-374-8800 X108
[email protected]

Source: NewLink Genetics Corporation

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Evercore ISI starts 'accelerating AI play' AMD (AMD) at Outperform
• Surgent Accounting & Financial Education to Premiere More Than a Dozen New Continuing Professional Education (CPE) Courses this Spring
• Williams Trading Downgrades Crocs (CROX) to Hold